We have previously demonstrated that inhibition of both ER and RAS signaling by fulvestrant and binimetinib induces tumor regression in WHIM16, which was identified previously as an NF1-depleted ER+ PDX model as measured by RNA-seq and Western blot analysis (9). This evidence concerns the gene NF1 and neoplasm.